ArticleThe journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians2014
Plasma concentrations of angiogenic/anti-angiogenic factors have prognostic value in women presenting with suspected preeclampsia to the obstetrical triage area: a prospective study.
Article in The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it, 86 citations in OpenAlex.
- Placental Growth Factor as a Prognostic Tool in Women With Hypertensive Disorders of Pregnancy: A Systematic Review.Hypertension (Dallas, Tex. : 1979) · 2017Pooled it
- Perinatal Endocrine-Cardiac Axis: A Narrative Review of Long-Term Cardiovascular Risks in Women with Gestational Diabetes, Hypertensive Disorders, and Thyroid Dysfunction.Biomedicines · 2026Review
- Maternal circulating sFlt-1/placental growth factor is a biomarker of fetal death associated with placental lesions of maternal vascular malperfusion.Journal of perinatal medicine · 2026Article
- Elevated sFlt-1/PlGF ratio in women with suspected or confirmed early-onset preeclampsia and super-imposed preeclampsia complicated by HELLP syndrome as well as abnormal umbilical artery Doppler findings and non-reassuring fetal status requiring immediate delivery: a prospective cohort study.Hypertension research : official journal of the Japanese Society of Hypertension · 2025Article
- Low-Molecular-Weight Heparin in Preeclampsia: Effects on Biomarkers and Prevention: A Narrative Review.Biomedicines · 2025Review
- Risk for Imminent Delivery in Preeclampsia Based on the sFlt-1/PlGF Ratio: Do We Need New Cut-Offs?Geburtshilfe und Frauenheilkunde · 2025Article
- Proteomic Profiles of Maternal Plasma Extracellular Vesicles for Prediction of Preeclampsia.American journal of reproductive immunology (New York, N.Y. : 1989) · 2024Article
- AC092100.1 promotes angiogenesis in pre-eclampsia through YTHDC2/VEGFA signaling.Functional & integrative genomics · 2024Article
- Preeclampsia at term: evidence of disease heterogeneity based on the profile of circulating cytokines and angiogenic factors.American journal of obstetrics and gynecology · 2024Article
- DEVELOPING A BEDSIDE TEST FOR PREECLAMPSIA: OVERCOMING SISYPHUS.Transactions of the American Clinical and Climatological Association · 2024Article
- Predictive value of the sFlt‑1/PlGF ratio in women with suspected preeclampsia: An update (Review).International journal of molecular medicine · 2023Article
- One-third of patients with eclampsia at term do not have an abnormal angiogenic profile.Journal of perinatal medicine · 2023Article
- Preeclampsia at term can be classified into 2 clusters with different clinical characteristics and outcomes based on angiogenic biomarkers in maternal blood.American journal of obstetrics and gynecology · 2023Article
- Human Plasma Proteome During Normal Pregnancy.Journal of proteome research · 2022Article
- Toward a new taxonomy of obstetrical disease: improved performance of maternal blood biomarkers for the great obstetrical syndromes when classified according to placental pathology.American journal of obstetrics and gynecology · 2022Article
- Imbalances in circulating angiogenic factors in the pathophysiology of preeclampsia and related disorders.American journal of obstetrics and gynecology · 2022Review
- The etiology of preeclampsia.American journal of obstetrics and gynecology · 2022Review
- Prediction of preeclampsia throughout gestation with maternal characteristics and biophysical and biochemical markers: a longitudinal study.American journal of obstetrics and gynecology · 2022Article
- Article
- The profiles of soluble adhesion molecules in the "great obstetrical syndromes"The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
Abstract
objectiveTo prospectively determine the prognostic value of maternal plasma concentrations of placental growth factor (PlGF), soluble endoglin (sEng) and soluble vascular endothelial growth factor receptors-1 and -2 (sVEGFR-1 and -2) in identifying patients with suspected preeclampsia (PE), who require preterm delivery (PTD) or develop adverse outcomes. STUDY
designThis prospective cohort study included 85 consecutive patients who presented to the obstetrical triage area at 20-36 weeks with a diagnosis of "rule out PE." Patients were classified as: 1) those who remained stable until term (n = 37); and 2) those who developed severe PE and required PTD (n = 48). Plasma concentrations of PlGF, sEng and sVEGFR-1 and -2 were determined by ELISA.
resultsPatients with PlGF/sVEGFR-1 ≤0.05 multiples of the median (MoM) or PlGF/sEng ≤0.07 MoM were more likely to deliver preterm due to PE [adjusted odd ratio (aOR) 7.4 and 8.8], and to develop maternal (aOR 3.7 and 2.4) or neonatal complications (aOR 10.0 and 10.1). Among patients who presented <34 weeks of gestation, PlGF/sVEGFR-1 ≤ 0.035 MoM or PlGF/sEng ≤0.05 MoM had a sensitivity of 89% (16/18), specificity of 96% (24/25) and likelihood ratio for a positive test of 22 to identify patients who delivered within 2 weeks. The addition of the PlGF/sVEGFR-1 ratio to standard clinical tests improved the sensitivity at a fixed false-positive rate of 3% (p = 0.004) for the identification of patients who were delivered due to PE within 2 weeks. Among patients who had a plasma concentration of PlGF/sVEGFR-1 ratio ≤0.035 MoM, 0.036-0.34 MoM and ≥0.35 MoM, the rates of PTD <34 weeks were 94%, 27% and 7%, respectively.
conclusionsThe determination of angiogenic/anti-angiogenic factors has prognostic value in patients presenting to the obstetrical triage area with suspected PE for the identification of those requiring preterm delivery and at risk for adverse maternal/neonatal outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.